The ability to evade immune monitoring and control is now considered an important functional hallmark of cancer.92,93 The CD4+CD25+Foxp3+ Treg are observed in several tumors and play a vital role in immune suppression of effector T cells.94 Hence, it can be posited that monoclonal antibodies against FGL2 may hinder Treg-mediated immune suppression in cancer. Here, IL2RA is linked to cancer.